Diurnal Group PLC Director Dealings (3039K)
December 12 2018 - 11:02AM
UK Regulatory
TIDMDNL
RNS Number : 3039K
Diurnal Group PLC
12 December 2018
12 December 2018
Diurnal Group plc
("Diurnal" or the "Company")
Director Dealings
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces the following Directors' dealings undertaken
for tax planning purposes:
Martin Whitaker, Chief Executive Officer, today sold 50,729
Ordinary Shares at a price of 21 pence per Ordinary Share and his
ISA purchased 50,729 Ordinary Shares at a price of 21.08 pence per
Ordinary Share. Following the transactions, Martin Whitaker's total
beneficial interest remains unchanged at 50,729 Ordinary Shares,
representing 0.08% of the total voting rights.
Details of the full notifications received by the Company are
set out below:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Martin Whitaker
------------------------------------ -------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------ -------------------------------------------------
b) Initial notification Initial notification
/Amendment
------------------------------------ -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------------------
a) Name Diurnal Group plc
------------------------------------ -------------------------------------------------
b) LEI 213800I2HNUNZN1LDH29
------------------------------------ -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 5 pence each in Diurnal
financial instrument, Group plc
type of instrument
Identification code GB00BDB6Q760
b) Nature of the transaction Sale and purchase of ordinary shares
------------------------------------ -------------------------------------------------
c) Price(s) and volume(s)
------------------------ --------------------
Price(s) Volume(s)
------------------------ --------------------
Sell 21p 50,729
------------------------------------------------------------------ --------------------
Buy 21.08p 50,729
------------------------------------------------------------------ --------------------
d) Aggregated information
- Aggregated volume As above
- Price
e) Date of the transaction 12 December 2018
------------------------------------ -------------------------------------------------
f) Place of the transaction XLON
------------------------------------ -------------------------------------------------
For further information, please visit www.diurnal.co.uk or contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
+44 (0)20 7894
Cantor Fitzgerald Europe (Joint Broker) 7000
Corporate Finance: Phil Davies, Will Goode,
Michael Boot
Healthcare Equity Sales: Andrew Keith
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLLFEEFALFLIT
(END) Dow Jones Newswires
December 12, 2018 11:02 ET (16:02 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024